Henk C.
- Country
- The Netherlands
- Department
- -
Research Overview
- Phase 3 Randomized Study of Telisotuzumab Vedotin vs. Docetaxel in c-Met Overexpressing EGFR Wildtype Non-Squamous NSCLC
- Phase 2 and 3 Evaluation of Adagrasib and Pembrolizumab in Advanced NSCLC with KRAS G12C Mutation
- Phase 3 Randomized, Double-Blind Study of Belrestotug and Dostarlimab Versus Pembrolizumab in PD-L1 High Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 64 of 285 partner sites.
Specializations
Lung Cancer Specialization
This investigator focuses on advanced therapeutic approaches for non-small cell lung cancer (NSCLC), with particular emphasis on treating specific genetic and molecular subtypes of the disease.
- KRAS G12C Mutation-Positive NSCLC
- c-Met Overexpressing NSCLC
- EGFR Wildtype NSCLC
Expertise extends to non-squamous NSCLC variants and their targeted treatment modalities.
Targeted Therapies
The investigator specializes in evaluating novel therapeutic agents for lung cancer treatment, including targeted biological therapies and immunotherapy combinations.
- Telisotuzumab Vedotin Applications
- Belrestotug-Dostarlimab Therapy
- Adagrasib Treatment Approaches
Focus includes assessment of treatment efficacy in specific patient populations based on molecular markers.
Immunotherapy Research
Specializes in immunotherapeutic approaches for lung cancer treatment, particularly focusing on PD-L1 expression and related therapeutic interventions.
- PD-L1 High Expression NSCLC
- Pembrolizumab-Based Treatments
- Combination Immunotherapy Strategies
Investigates both monotherapy and combination approaches in previously untreated and treatment-experienced patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.